Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
This study is ongoing, but not recruiting participants.
Sponsored by: Novartis
Information provided by: Novartis
ClinicalTrials.gov Identifier: NCT00171925
  Purpose

Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant plasma cells induce osteolytic lesions, which is characteristic for progression of multiple myeloma. It is the aim of this study to investigate whether zoledronic acid has an influence on the progression of multiple myeloma.


Condition Intervention Phase
Multiple Myeloma Stage I
Drug: Zoledronic acid
Phase III

Genetics Home Reference related topics: aceruloplasminemia hemophilia
MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Zoledronic acid
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Effect of zoledronic acid on progression free survival

Secondary Outcome Measures:
  • Overall survival
  • Show superiority of zoledronic acid for development of Skeletal complications
  • Quality of Life
  • Bone markers

Estimated Enrollment: 220
Study Start Date: September 2000
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Evidence of myeloma according to the criteria of the British Columbia Cancer Agency (for the diagnosis, 2 of the 3 criteria must be met):

    • Evidence of paraprotein in the serum or urine
    • Bone marrow infiltration with plasma cells which represent more than 10% of the nucleated cells
    • Radiologically, at least one osteolytic lesion
  • Asymptomatic patients with Stage I (Durie and Salmon) multiple myeloma

Exclusion criteria:

  • Patients with more than one osteolytic lesion on conventional skeletal radiography
  • Previous treatment with bisphosphonates
  • bilirubin > 2.5 mg/dl
  • Abnormal renal function as evidenced by

A calculated creatinine clearance < 30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula:

CrCl= [140-age (years)] x weight (kg) {x 0.85 for female patients} [72 x serum creatinine (mg/dL)]

  • Patients with other malignant diseases or severe concomitant diseases
  • Potentially fertile patients who are not using a reliable and appropriate method of contraception
  • Pregnancy or breast-feeding
  • Participation in another clinical study with an investigational drug within 12 weeks of study entry
  • Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
  • Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)

Other protocol-defined inclusion and exclusion criteria may apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00171925

Locations
Germany
Berlin, Germany
Sponsors and Collaborators
Novartis
Investigators
Study Chair: Novartis Novartis
  More Information

Study ID Numbers: CZOL446 DE01
Study First Received: September 13, 2005
Last Updated: May 1, 2008
ClinicalTrials.gov Identifier: NCT00171925  
Health Authority: United States: Food and Drug Administration;   Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
Multiple Myeloma
Stage I
Zoledronic acid
Progression

Study placed in the following topic categories:
Zoledronic acid
Immunoproliferative Disorders
Blood Protein Disorders
Hematologic Diseases
Blood Coagulation Disorders
Disease Progression
Vascular Diseases
Paraproteinemias
Hemostatic Disorders
Multiple Myeloma
Diphosphonates
Hemorrhagic Disorders
Multiple myeloma
Lymphoproliferative Disorders
Neoplasms, Plasma Cell

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Immune System Diseases
Physiological Effects of Drugs
Bone Density Conservation Agents
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009